Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816084 | 0.77 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL3817449 | 0.75 | — | — | |
| SCHEMBL4477774 | 0.75 | MAPT (0.35) | CYP2A6 | |
| SCHEMBL3483532 | 0.75 | CYP2A6 (0.46) | CYP2A6 | |
| SCHEMBL5489699 | 0.73 | CYP2A6 (0.49) | CYP2A6 | |
| SCHEMBL18936126 | 0.72 | CYP2A6 (0.51) | CYP2A6 | |
| SCHEMBL4302016 | 0.71 | — | — | |
| SCHEMBL4458560 | 0.71 | TUBB4A (0.34) | — | |
| SCHEMBL3483296 | 0.71 | CYP2A6 (0.58) | CYP2A6 | |
| SCHEMBL546825 | 0.69 | CYP2A6 (0.50) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | claimed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | claimed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | claimed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | CYP2A6 3427/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CYP2A6 131/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CYP2A6 131/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | CYP2A6 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.